N-(3,4-dimethoxyphenethyl)-2,6-dimethylthieno[2,3-d]pyrimidin-4-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3,4-dimethoxyphenethyl)-2,6-dimethylthieno[2,3-d]pyrimidin-4-amine
• 英文别名: N-[2-(3,4-dimethoxyphenyl)ethyl]-2,6-dimethylthieno[2,3-d]pyrimidin-4-amine
• 化学式: C₁₈H₂₁N₃O₂S
• 分子量: 343.45
• InChiKey: ZEBYWXDZWYNANQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  84.5
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Novel Thieno-Pyridine and Thieno-Pyrimidine Derivatives and Their Use as Positive Allosteric Modulators of Mglur2-Receptors
  申请人：Imogai Julien Hassan

  公开号：US20070275984A1

  公开（公告）日：2007-11-29

  The present invention relates to novel compounds, in particular novel thieno-pyridine and thieno-pyrimidine derivatives according to Formula (I), wherein all radicals are defined in the application. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及一种新颖的化合物，特别是公式（I）中定义的新颖噻吩-吡啶和噻吩-嘧啶衍生物，其中所有基团在申请中定义。本发明的化合物是代谢型受体亚型2（“mGluR2”）的正向变构调节剂，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及代谢型受体mGluR2亚型的疾病。特别是，这些疾病是从焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统疾病组中选择的。本发明还涉及制备这种化合物和制剂的制药组合物和制备过程，以及利用这种化合物预防和治疗涉及mGluR2的疾病。